Anat Wieder-Finesod, Dafna Yahav, Carmit Rubin, Shirley Hashkor, Jo Southern, Gabriel Mircus, Christian Theilacker, Ron Dagan, Gili Regev-Yochay
{"title":"各种血清型引起的侵袭性肺炎球菌疾病的病死率--2009-2018 年以色列全国监测数据分析。","authors":"Anat Wieder-Finesod, Dafna Yahav, Carmit Rubin, Shirley Hashkor, Jo Southern, Gabriel Mircus, Christian Theilacker, Ron Dagan, Gili Regev-Yochay","doi":"10.1016/j.cmi.2024.11.018","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The 20-valent pneumococcal conjugate vaccine (PCV20) has been introduced in Israel. Its public health benefit depends on its effect on mortality caused by PCV20 serotypes not present in PCV13 (PCV20non13). We aimed to describe invasive pneumococcal disease (IPD) characteristics and case fatality rate among adults by serotypes.</p><p><strong>Methods: </strong>We analysed data from the Israeli nationwide surveillance database of IPD in adults, 2009-2018. The primary outcome was in-hospital case fatality rate (CFR) within 30 days, focusing on specific serotypes. Adjusted odds ratios (aORs) for association between PCV20non13 serotypes and mortality were calculated using logistic regression.</p><p><strong>Results: </strong>Overall, 3864 IPD episodes were reported, 3733 (96.6%) with known serotype, 54% (1705/3123) were in men; 54% (1997/3733) were aged ≥65 years. PCV13-IPD cases constituted 40% of all IPD and decreased during study years. PCV20non13 and nonPCV20 serotypes constituted 26% and 34% of cases, respectively, and increased over time. The most frequent non-PCV13 serotypes detected were PCV20non13 serotypes 8 (8%), 12F (7.2%), 22F (3%); and nonPCV20 serotype 16F (5%). In-hospital CFR was 22% (698/3140). CFR for PCV13 serotype was 21.1% (265/1255); for PCV20non13 - 16.2% (124/766); and for nonPCV20 CFR - 28.5% (289/1014). Among PCV20non13 serotypes compared to PCV13 serotypes, 11A was associated with higher CFR (41%, aOR 3.1, 95% CI 1.64-5.83), while serotype 8 was associated with lower CFR (8%, aOR 0.5, 95% CI 0.3-0.8).</p><p><strong>Conclusions: </strong>PCV20non13 serotypes constituted 26% of all adult IPD in the post-PCV13 era. CFR from PCV20non13 serotype IPD was comparable to that from PCV13 serotypes. These data support the potential added benefit of PCV20 in reducing mortality from IPD, though mortality remains substantial from nonPCV20 serotypes. Future IPD-related mortality will depend on the evolution of serotype distribution over time.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case-fatality rate of invasive pneumococcal disease caused by various serotypes - an analysis of nationwide surveillance data from Israel, 2009-2018.\",\"authors\":\"Anat Wieder-Finesod, Dafna Yahav, Carmit Rubin, Shirley Hashkor, Jo Southern, Gabriel Mircus, Christian Theilacker, Ron Dagan, Gili Regev-Yochay\",\"doi\":\"10.1016/j.cmi.2024.11.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The 20-valent pneumococcal conjugate vaccine (PCV20) has been introduced in Israel. Its public health benefit depends on its effect on mortality caused by PCV20 serotypes not present in PCV13 (PCV20non13). We aimed to describe invasive pneumococcal disease (IPD) characteristics and case fatality rate among adults by serotypes.</p><p><strong>Methods: </strong>We analysed data from the Israeli nationwide surveillance database of IPD in adults, 2009-2018. The primary outcome was in-hospital case fatality rate (CFR) within 30 days, focusing on specific serotypes. Adjusted odds ratios (aORs) for association between PCV20non13 serotypes and mortality were calculated using logistic regression.</p><p><strong>Results: </strong>Overall, 3864 IPD episodes were reported, 3733 (96.6%) with known serotype, 54% (1705/3123) were in men; 54% (1997/3733) were aged ≥65 years. PCV13-IPD cases constituted 40% of all IPD and decreased during study years. PCV20non13 and nonPCV20 serotypes constituted 26% and 34% of cases, respectively, and increased over time. The most frequent non-PCV13 serotypes detected were PCV20non13 serotypes 8 (8%), 12F (7.2%), 22F (3%); and nonPCV20 serotype 16F (5%). In-hospital CFR was 22% (698/3140). CFR for PCV13 serotype was 21.1% (265/1255); for PCV20non13 - 16.2% (124/766); and for nonPCV20 CFR - 28.5% (289/1014). Among PCV20non13 serotypes compared to PCV13 serotypes, 11A was associated with higher CFR (41%, aOR 3.1, 95% CI 1.64-5.83), while serotype 8 was associated with lower CFR (8%, aOR 0.5, 95% CI 0.3-0.8).</p><p><strong>Conclusions: </strong>PCV20non13 serotypes constituted 26% of all adult IPD in the post-PCV13 era. CFR from PCV20non13 serotype IPD was comparable to that from PCV13 serotypes. These data support the potential added benefit of PCV20 in reducing mortality from IPD, though mortality remains substantial from nonPCV20 serotypes. Future IPD-related mortality will depend on the evolution of serotype distribution over time.</p>\",\"PeriodicalId\":10444,\"journal\":{\"name\":\"Clinical Microbiology and Infection\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":10.9000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmi.2024.11.018\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.11.018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Case-fatality rate of invasive pneumococcal disease caused by various serotypes - an analysis of nationwide surveillance data from Israel, 2009-2018.
Objectives: The 20-valent pneumococcal conjugate vaccine (PCV20) has been introduced in Israel. Its public health benefit depends on its effect on mortality caused by PCV20 serotypes not present in PCV13 (PCV20non13). We aimed to describe invasive pneumococcal disease (IPD) characteristics and case fatality rate among adults by serotypes.
Methods: We analysed data from the Israeli nationwide surveillance database of IPD in adults, 2009-2018. The primary outcome was in-hospital case fatality rate (CFR) within 30 days, focusing on specific serotypes. Adjusted odds ratios (aORs) for association between PCV20non13 serotypes and mortality were calculated using logistic regression.
Results: Overall, 3864 IPD episodes were reported, 3733 (96.6%) with known serotype, 54% (1705/3123) were in men; 54% (1997/3733) were aged ≥65 years. PCV13-IPD cases constituted 40% of all IPD and decreased during study years. PCV20non13 and nonPCV20 serotypes constituted 26% and 34% of cases, respectively, and increased over time. The most frequent non-PCV13 serotypes detected were PCV20non13 serotypes 8 (8%), 12F (7.2%), 22F (3%); and nonPCV20 serotype 16F (5%). In-hospital CFR was 22% (698/3140). CFR for PCV13 serotype was 21.1% (265/1255); for PCV20non13 - 16.2% (124/766); and for nonPCV20 CFR - 28.5% (289/1014). Among PCV20non13 serotypes compared to PCV13 serotypes, 11A was associated with higher CFR (41%, aOR 3.1, 95% CI 1.64-5.83), while serotype 8 was associated with lower CFR (8%, aOR 0.5, 95% CI 0.3-0.8).
Conclusions: PCV20non13 serotypes constituted 26% of all adult IPD in the post-PCV13 era. CFR from PCV20non13 serotype IPD was comparable to that from PCV13 serotypes. These data support the potential added benefit of PCV20 in reducing mortality from IPD, though mortality remains substantial from nonPCV20 serotypes. Future IPD-related mortality will depend on the evolution of serotype distribution over time.
期刊介绍：
Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
